Cancer Research Landon Prizes for Basic and Translational Cancer Research  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 48, 5645-5649, October 15, 1988]
© 1988 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gelvan, D.
Right arrow Articles by Samuni, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gelvan, D.
Right arrow Articles by Samuni, A.

Reappraisal of the Association between Adriamycin and Iron1

Dan Gelvan2 and Amram Samuni

Department of Molecular Biology, Hebrew University-Hadassah Medical School, Jerusalem 91010, Israel

The nature of the association between Adriamycin (ADR) and iron was reinvestigated spectroscopically. It is shown that ADR and Fe3+ do not necessarily form a colloidal aggregate, but rather form a true chelate, Fe3+ ADR3, having a 602-nm molar extinction coefficient of 16.4 mM-1·cm-1. In contrast to the high nominal binding constant for ferric-ADR, ß = 1033.4, it is shown that under actual conditions of metal hydrolysis and ADR protonation, the effective binding constant, Keff, is strongly pH dependent and is only 1016.2M-3 at pH 7.4. These properties are reflected in a progressive dissociation of Fe3+ ADR3 upon dilution and at decreasing pH. Maximal iron chelation by ADR is not achieved at [ADR]:[iron] ratios lower than 10:1, and at [ADR] below the 0.1 mM range. These observations necessitate a reevaluation of previous conclusions regarding the involvement of iron in ADR activity. The clinical implications are important, because at ADR concentrations obtained in vivo, and contrary to common assumptions, ADR will not bind adventitious iron to form a binary chelate. Furthermore, a preformed Fe3+ ADR3 chelate will dissociate when injected. This precludes the involvement of a binary ferric-ADR chelate in the mechanism of action of ADR in vivo.

1 This research was supported by Grant 85-00246 from the U. S.-Israel Binational Science Foundation, Jerusalem, Israel.

2 To whom requests for reprints should be addressed.

Received 2/16/88. Revised 6/23/88. Accepted 7/ 5/88.




This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
S. M. Zeman, D. R. Phillips, and D. M. Crothers
Characterization of covalent Adriamycin-DNA adducts
PNAS, September 29, 1998; 95(20): 11561 - 11565.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1988 by the American Association for Cancer Research.